Invivocue aims to advance medical research,
leading to improved healthcare outcomes in areas including oncology, inflammation and infectious disease.
Invivocue was formed as a joint venture between Invitrocue, an innovative life sciences company providing in vitro liver models for drug toxicology testing, as well as 3D patient-derived organoid technology for personalised oncology, and Dr Chen Qing Feng, a Senior Principal Investigator at the Institute of Molecular and Cell Biology, whose research expertise focused on humanised mouse models for various disease applications.
Invivocue’s technologies are built upon decades of research conducted at national research institutes, organisations and industry in Singapore. Our animal models have enabled research in areas such as oncology, liver disease, auto-immune and infectious diseases.About Us